Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.05
- Piotroski Score 4.00
- Grade Buy
- Symbol (TBPH)
- Company Theravance Biopharma, Inc.
- Price $8.05
- Changes Percentage (-0.62%)
- Change -$0.05
- Day Low $8.03
- Day High $8.15
- Year High $11.71
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $15.00
- High Stock Price Target $21.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.89
- Trailing P/E Ratio -9.85
- Forward P/E Ratio -9.85
- P/E Growth -9.85
- Net Income $-55,193,000
Income Statement
Quarterly
Annual
Latest News of TBPH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation
Even if a company is not profitable, its stock may not necessarily decline. For instance, Theravance Biopharma has managed its cash burn effectively, with a solid cash runway and reduced spending. Ana...
By Yahoo! Finance | 3 weeks ago -
Need To Know: Analysts Just Made A Substantial Cut To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Estimates
Theravance Biopharma, Inc. faced a downgrade in revenue and earnings forecasts by analysts, impacting shareholder sentiment. Despite a cut in estimates, the company is expected to see revenue growth s...
By Yahoo! Finance | 1 month ago -
Theravance Biopharma, Inc. (NASDAQ:TBPH): When Will It Breakeven?
Theravance Biopharma, Inc., a biopharmaceutical company focused on respiratory medicines, is expected to reach profitability in 2025 according to industry analysts....
By Yahoo! Finance | 2 months ago
